ArticleEuropean radiology2022
Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 73 citations in OpenAlex.
- Imaging in localized intrahepatic bile duct dilatation: a pictorial review of diagnostic and differential approaches.Insights into imaging · 2026Article
- Beyond Gilbert syndrome: exploring the heterozygous UGT1A1 c.41_40dup variant as a potential modifier of bile composition associated with a cholangiopathic phenotype in adults with unexplained chronic cholestasis.BMC gastroenterology · 2026Article
- Prevalence, interreader agreement, and prognostic value of high-grade and relevant strictures in individuals with primary sclerosing cholangitis.European radiology · 2026Article
- Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?European radiology · 2026Article
- Diagnostic Imaging of Pancreatic and Biliary Involvement in IgG4-Related Disease: Key Imaging Features, Diagnostic Criteria and Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis.Internal medicine journal · 2026Article
- Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.BMC medical imaging · 2026Article
- Quantitative MRCP as Part of Primary Sclerosing Cholangitis Standard of Care in the National Health Service in England: A Feasibility Assessment Among Hepatologists.Healthcare (Basel, Switzerland) · 2025Article
- ESGAR consensus statement on MR imaging in primary sclerosing cholangitis.European radiology · 2025Article
- MR imaging and cholangiography show suboptimal performance for diagnosing ductal cholangiocarcinoma in primary sclerosing cholangitis patients.European radiology · 2025Article
- Article
- Exploring the Role of MRCP+ for Enhancing Detection of High-Grade Strictures in Primary Sclerosing Cholangitis.Journal of clinical medicine · 2025Article
- Unmet needs in autoimmune liver diseases.Current opinion in immunology · 2025Review
- Endoscopic management of primary sclerosing cholangitis.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025Review
- Benign biliary conditions with increased risk of malignant lesions.Abdominal radiology (New York) · 2025Review
- Ultrasound of Bile Ducts-An Update on Measurements, Reference Values, and Their Influencing Factors.Diagnostics (Basel, Switzerland) · 2025Review
- Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025Review
- Initial Magnetic Resonance Imaging Findings in Hepatic Fascioliasis and Serological and Radiological Response After Triclabendazole Treatment.The American journal of tropical medicine and hygiene · 2025Article
- Pandemic COVID-19 as a challenge for telemedicine in the Czech Republic.The International journal of health planning and management · 2025Article
- Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis.Frontiers in pharmacology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disorder affecting the bile ducts and is characterized by biliary strictures, progressive liver parenchymal fibrosis, and an increased risk of hepatobiliary malignancies primarily cholangiocarcinoma (CCA). PSC may lead to portal hypertension, liver decompensation, and liver failure with the need for liver transplantation. Magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) are considered the imaging standard for diagnosis and follow-up in patients with PSC. Currently, there are no universally accepted reporting standards and definitions for MRI/MRCP features. Controversies exist about the definition of a high-grade stricture and there is no widely agreed approach to their management. The members of the MRI working group of the International Primary Sclerosing Cholangitis Study Group (IPSCSG) sought to define terminologies and reporting standards for describing MRI/MRCP features that would be applied to diagnosis and surveillance of disease progression, and potentially for evaluating treatment response in clinical trials. In this extensive review, the technique of MRI/MRCP and assessment of image quality for the evaluation of PSC is briefly described. The definitions and terminologies for severity and length of strictures, duct wall thickening and hyperenhancement, and liver parenchyma signal intensity changes are outlined. As CCA is an important complication of PSC, standardized reporting criteria for CCA developing in PSC are summarized. Finally, the guidelines for reporting important changes in follow-up MRI/MRCP studies are provided. KEY POINTS: • Primary sclerosing cholangitis is a chronic inflammatory disorder affecting the bile ducts, causing biliary strictures and liver fibrosis and an increased risk of cholangiocarcinoma. • This consensus document provides definitions and suggested reporting standards for MRI and MRCP features of primary sclerosing cholangitis, which will allow for a standardized approach to diagnosis, assessment of disease severity, follow-up, and detection of complications. • Standardized definitions and reporting of MRI/MRCP features of PSC will facilitate comparison between studies, promote longitudinal assessment during management, reduce inter-reader variability, and enhance the quality of care and communication between health care providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.